PE20150764A1 - Niclosamida para el tratamiento de tumores solidos - Google Patents

Niclosamida para el tratamiento de tumores solidos

Info

Publication number
PE20150764A1
PE20150764A1 PE2015000153A PE2015000153A PE20150764A1 PE 20150764 A1 PE20150764 A1 PE 20150764A1 PE 2015000153 A PE2015000153 A PE 2015000153A PE 2015000153 A PE2015000153 A PE 2015000153A PE 20150764 A1 PE20150764 A1 PE 20150764A1
Authority
PE
Peru
Prior art keywords
niclosamide
treatment
solid tumors
derivatives
combination
Prior art date
Application number
PE2015000153A
Other languages
English (en)
Inventor
Bjorn Scheffler
Martin Glas
Original Assignee
Life And Brain Gmbh
Univ Bonn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48917552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150764(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Life And Brain Gmbh, Univ Bonn filed Critical Life And Brain Gmbh
Publication of PE20150764A1 publication Critical patent/PE20150764A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La invencion se refiere a usos terapeuticos novedosos de la niclosamida para el tratamiento del cancer. En particular, se proporciona una combinacion de niclosamida o uno de sus derivados con un agente alquilante para el tratamiento de tumores solidos. Por otra parte, la niclosamida o uno de sus derivados se pueden utilizar para el tratamiento de tumores solidos caracterizados por infraexpresion de NFkBIA. Finalmente, la invencion se refiere a metodos de diagnostico para determinar si el tratamiento con niclosamida, solo o en combinacion con un agente alquilante, es adecuado para un paciente de cancer
PE2015000153A 2012-08-06 2013-08-06 Niclosamida para el tratamiento de tumores solidos PE20150764A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/065364 WO2014023329A1 (en) 2012-08-06 2012-08-06 Niclosamide and its derivatives for use in the treatment of solid tumors

Publications (1)

Publication Number Publication Date
PE20150764A1 true PE20150764A1 (es) 2015-06-04

Family

ID=48917552

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000153A PE20150764A1 (es) 2012-08-06 2013-08-06 Niclosamida para el tratamiento de tumores solidos

Country Status (15)

Country Link
US (1) US9844522B2 (es)
EP (1) EP2879671A1 (es)
JP (1) JP6272861B2 (es)
CN (1) CN104936586A (es)
AU (1) AU2013301542A1 (es)
BR (1) BR112015002706A8 (es)
CA (1) CA2880916A1 (es)
CL (1) CL2015000289A1 (es)
IL (1) IL237125A0 (es)
MX (1) MX2015001716A (es)
PE (1) PE20150764A1 (es)
PH (1) PH12015500252A1 (es)
RU (1) RU2015107753A (es)
SG (1) SG11201500912XA (es)
WO (2) WO2014023329A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3313388A4 (en) 2015-06-24 2019-05-15 Duke University CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE
BR112018004069A2 (pt) 2015-09-01 2021-07-13 First Wave Bio, Inc. composição farmacêutica sólida, preparação de enema compreendendo niclosamida, formulação de enema, uso de niclosamida e kit
US20180271809A1 (en) * 2015-09-16 2018-09-27 Agency For Science, Technology And Research Use of niclosamide in the treatment of p53-deficient cells
TWI638825B (zh) 2016-01-12 2018-10-21 臺北醫學大學 抑制癌症及病毒之化合物
EP3407848A1 (en) * 2016-01-26 2018-12-05 The Procter and Gamble Company Absorbent cores with high molecular weight superabsorbent immobilizer
CN105687171A (zh) * 2016-01-28 2016-06-22 昆明医科大学 一种阿米诺喹的新用途
TWI631944B (zh) 2016-10-14 2018-08-11 長庚大學 氯硝柳胺及其衍生物的用途
US20210041443A1 (en) * 2018-04-24 2021-02-11 Universidade Do Minho Wnt6 as glioblastoma oncogenic biomarker, and uses of inhibitors thereof
US20210179615A1 (en) * 2018-07-30 2021-06-17 Duke University Niclosamide analogues and therapeutic use thereof
WO2021142238A1 (en) * 2020-01-10 2021-07-15 First Wave Bio, Inc. Deuterated niclosamide
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
WO2022124525A1 (ko) * 2020-12-08 2022-06-16 주식회사 대웅제약 니클로사마이드를 포함하는 근육내 및/또는 피하 투여용 약학적 조성물
CN114601833A (zh) * 2022-04-02 2022-06-10 北京大学口腔医学院 一种治疗肿瘤的化学药物组合

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US7256201B2 (en) * 2000-12-07 2007-08-14 Astrazeneca Ab Selective estrogen receptor-β ligands
JP4452899B2 (ja) * 2001-12-13 2010-04-21 味の素株式会社 新規フェニルアラニン誘導体
ATE446077T1 (de) 2002-05-02 2009-11-15 Univ Rochester Vektoren mit beiden isoformen von beta- hexosaminidase
AU2003249244A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
WO2005060951A2 (en) * 2003-12-19 2005-07-07 Bionaut Pharmaceuticals, Inc. Anti-neoplastic agents, combination therapies and related methods
US20060009506A1 (en) * 2004-07-09 2006-01-12 Odyssey Thera, Inc. Drugs for the treatment of neoplastic disorders
US8163744B2 (en) * 2005-03-18 2012-04-24 Nexuspharma, Inc. Tetrahydro-isoquinolin-1-ones for the treatment of cancer
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
US20130023498A1 (en) * 2008-02-20 2013-01-24 The Wistar Institute and North Carolina State University MicroRNA Modulators and Method for Identifying and Using the Same
WO2009148623A2 (en) * 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
US8580267B2 (en) * 2008-12-19 2013-11-12 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
WO2012172069A1 (en) * 2011-06-15 2012-12-20 Life And Brain Gmbh Glioblastoma inhibiting compounds and their use
CN103930132A (zh) * 2011-09-27 2014-07-16 拜奥迈德瓦利探索有限公司 治疗胶质瘤的组合物和方法

Also Published As

Publication number Publication date
EP2879671A1 (en) 2015-06-10
RU2015107753A (ru) 2016-09-27
CA2880916A1 (en) 2014-02-13
US20150174086A1 (en) 2015-06-25
PH12015500252A1 (en) 2015-03-30
WO2014023329A1 (en) 2014-02-13
WO2014023732A1 (en) 2014-02-13
MX2015001716A (es) 2015-12-08
IL237125A0 (en) 2015-03-31
BR112015002706A2 (pt) 2017-08-08
BR112015002706A8 (pt) 2017-10-10
CN104936586A (zh) 2015-09-23
SG11201500912XA (en) 2015-04-29
CL2015000289A1 (es) 2015-06-12
US9844522B2 (en) 2017-12-19
AU2013301542A1 (en) 2015-02-19
JP2015528437A (ja) 2015-09-28
JP6272861B2 (ja) 2018-01-31

Similar Documents

Publication Publication Date Title
PE20150764A1 (es) Niclosamida para el tratamiento de tumores solidos
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
UA110473C2 (uk) Спосіб лікування раку за допомогою пухлиноасоційованого антигену, отриманого із цикліну d1
TWD161529S (zh) 治療燈
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
MX2021003858A (es) Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
EA201590554A1 (ru) Ингибиторы глюкозилцерамид-синтазы
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
ECSP12012024A (es) Terapia combinada para el tratamiento del cáncer y ensayos de diagnóstico relacionados
CL2015002807A1 (es) Terapia de combinación
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
BR112015008612A2 (pt) métodos de tratamento utilizando adenovirus
PL2771329T3 (pl) Nowe związki di-podstawione 3,4-diamino-3-cyklobuteno- 1,2-dionu do zastosowania w leczeniu patologii, w których pośredniczą chemokiny
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos
CR20140400A (es) Terapia combinada para el tratamiento del cancer de ovario
MX2015014344A (es) Terapia contra el cancer.
WO2013185764A3 (en) Pharmaceutical compositions for combination therapy
AR090129A1 (es) Oligonucleotidos para la modulacion de la expresion genica y sus usos
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
NI201100228A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cáncer.
CL2018002686A1 (es) Marcador para predecir la respuesta al tratamiento del agente anticancerígeno en pacientes con cáncer.
MX2014014839A (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.

Legal Events

Date Code Title Description
FD Application declared void or lapsed